Evans syndrome future or investigational therapies

Jump to navigation Jump to search

Evans syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Evans syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Evans syndrome future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Evans syndrome future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Evans syndrome future or investigational therapies

CDC on Evans syndrome future or investigational therapies

Evans syndrome future or investigational therapies in the news

Blogs on Evans syndrome future or investigational therapies

Directions to Hospitals Treating Evans syndrome

Risk calculators and risk factors for Evans syndrome future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Future or Investigational Therapies

In a patient with refractory disease, an allogeneic hematopoietic stem cell transplant (HSCT) resulted in complete clinical and serologic remission for more than 30 months. Allogeneic HSCT may be the only current curative therapy for Evans syndrome, but may also be complicated by significant toxicities. In more serious cases no cure exists.

References